Continuation: UMMC's Clinical Center in NIDDK's Gastroparesis Research

描述（由申请人提供）：密西西比大学医学中心建议继续作为临床中心参与NIDDK的胃轻瘫临床研究联盟。我们的研究团队由胃轻瘫领域公认的研究和临床经验专家托马斯阿贝尔博士领导，现在将包括生物统计学专家Michael格里斯沃尔德博士作为共同研究者，以及数据自动化、信号分析、数据融合和仪器专家Filip To博士作为合作者，沿着的还有我们最初研究团队的主要成员和两名分别来自外科和病理学的UMC合作者。该团队提供的多学科专业知识将进一步提高我们研究与胃轻瘫相关的复杂病理生理途径和症状的能力。UMMC负责卫生事务的副校长和负责研究的副校长继续为开展临床中心的研究提供强有力的支持和必要的资源。 关于联盟范围内的贡献，UMMC处于有利地位，可以通过其临床中心增加已入组胃轻瘫登记研究的研究人群。每年约有1000名胃轻瘫患者在该中心寻求治疗;在过去5年中，我们评估了该疾病的新患者，平均每年确定300名新的胃轻瘫患者。除了促进联盟范围内的协议外，UMMC在当前资助期间还提出了两项新的努力。第一个是评估和比较糖尿病和特发性病因的GP患者的GI症状、Cajal间质细胞的组织学计数和电生理学测量之间的关联，以及比较这些活检标本中的ICC计数与来自对照的胃组织标本中的计数。第二个目的是证明胃电刺激（GES）可以将个体患者的GI症状减少至少50%，以评估临时GES对胃排空时间、EGG值、神经激素和自主状态标志物以及HRQOL测量的影响，并评估在不同GES能量水平下的EGG值，以预测GES的可能有用性。

DESCRIPTION (provided by applicant): The University of Mississippi Medical Center proposes to continue its participation as a Clinical Center in NIDDK's Gastroparesis Clinical Research Consortium. Our study team, headed by Thomas Abell, MD, a recognized expert in research and clinical experience in the area of gastroparesis, will now include as co- investigator Michael Griswold, PhD, an expert in biostatistics, and as collaborator Filip To, PhD, an expert in data automation, signal analysis, data fusion, and instrumentation, along with key members of our initial research team and two UMC collaborators from Surgery and Pathology, respectively. The multidisciplinary expertise provided by this team will further our ability to investigate the complex pathophysiological pathways and symptoms associated with gastroparesis. The UMMC Vice Chancellor for Health Affairs and the Associate Vice Chancellor for Research continue to provide strong support for and the resources necessary to conducting the Clinical Center's research. With respect to Consortium-wide contributions, UMMC is well positioned to increase the study population already enrolled in the Gastroparesis Registry through its Clinical Center. Approximately 1000 patients with gastroparesis annually seek their treatment at this site; over the past 5 years, we have evaluated new patients for the disorder, identifying on the average 300 new patients with gastroparesis each year. In addition to furthering Consortium-wide protocols, two new-efforts have been proposed for the present funding period at UMMC. The first is to assess and compare associations between presenting Gl symptoms, histological counts of interstitial cells of Cajal, and electrophysiology measures for patients with GP of diabetic and idiopathic etiology, as well as to compare ICC counts in these biopsy specimens with counts in gastric tissue specimens from controls. The second is to demonstrate that Gastric Electrical Stimulation (GES) can reduce Gl symptoms by at least 50% for individual patients, to assess the impact of temporary GES on gastric emptying times, EGG values, neuro-hormonal and autonomic status markers, and HRQOL measures, and to evaluate EGG values at varied GES energy levels in predicting likely usefulness with GES.